When.com Web Search

  1. Ads

    related to: action of ezetimibe

Search results

  1. Results From The WOW.Com Content Network
  2. Ezetimibe - Wikipedia

    en.wikipedia.org/wiki/Ezetimibe

    Ezetimibe, sold under the brand name Zetia among others, is a medication used to treat high blood cholesterol and certain other lipid abnormalities. [ 3 ] [ 4 ] Generally it is used together with dietary changes and a statin . [ 5 ]

  3. Cardiovascular agents - Wikipedia

    en.wikipedia.org/wiki/Cardiovascular_agents

    Antihypertensive agents are classified according to their mechanism of actions. The most common classes prescribed are diuretics, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), calcium channel blockers (CCBs) and beta-blockers. Antihyperlipidemic agents most often prescribed are statins, ezetimibe and ...

  4. Ezetimibe/rosuvastatin - Wikipedia

    en.wikipedia.org/wiki/Ezetimibe/rosuvastatin

    Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol. [ 6 ] [ 7 ] In some countries it is sold as a kit or a pack containing two distinct pills.

  5. Ezetimibe/atorvastatin - Wikipedia

    en.wikipedia.org/wiki/Ezetimibe/atorvastatin

    Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]

  6. FDA Approves Merck's LIPTRUZET™ (ezetimibe and ... - AOL

    www.aol.com/news/2013-05-03-fda-approves-mercks...

    FDA Approves Merck's LIPTRUZET™ (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol LIPTRUZET Approved for Patients with Primary or Mixed Hyperlipidemia ...

  7. Ezetimibe/simvastatin - Wikipedia

    en.wikipedia.org/wiki/Ezetimibe/simvastatin

    With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]